---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-032071"
form_type: "8-K"
ticker: "OSTX"
cik: "0001795091"
company_name: "OS Therapies Inc"
filed_at: "2025-04-15T23:59:59+00:00"
generated_at: "2026-05-23T14:50:43.092729+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# OS Therapies closes $8M asset acquisition from Ayala; eliminates $20M milestones, cuts royalty to 1.5%

## Summary
- Total consideration $8M: $400k cash to Ayala, $100k to third party, $7.5M in stock (4,774,637 shares at VWAP).
- Eliminated $3.5M Biologics License filing milestone and $16.5M in sales milestones for OST-HER2.
- Royalty on OST-HER2, ADXS-503, ADXS-504 reduced from 10% to 1.5% of net sales (to Univ. of Pennsylvania).
- Added three clinical-stage candidates (OST-AXAL for HPV, OST-503 for NSCLC, OST-PSA for prostate) and 8 preclinical constructs.
- Issued 2,164,215 shares and a warrant for 2,166,381 shares (exercise $0.001, 3-yr term); additional 444,041 shares pending stockholder approval.

## SEC filing metadata
- accession: 0001213900-25-032071
- form_type: 8-K
- ticker: OSTX
- cik: 0001795091
- company_name: OS Therapies Inc
- filed_at: 2025-04-15T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.01, 3.02, 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1795091/000121390025032071/0001213900-25-032071-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1795091/000121390025032071/ea0238051-8k_ostherapies.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-032071
- JSON: https://secwatch.observer/filing/0001213900-25-032071.json
- Plain text: https://secwatch.observer/filing/0001213900-25-032071.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.